Optimize R&D
Industry challenges
Nowadays R&D organisations are under huge pressure as their productivity remains unsatisfactory despite the massive increases in R&D spend and significant efforts on improving operational excellence.
Due to the poor R&D results the last couple of years (very low new molecular entity approvals) and with the fact that 25% of big pharma sales go off patent by 2012, immediate actions are required, the current business model has to be re-invented.
The R&D practice of the future will have to cope with:
- Increasing development and patients cost;
- Patient safety as key factor for confidence and trust;
- Efficient pipeline management to improve the output;
- Appropriate Intellectual Property management to facilitate innovation;
- Evolving stakeholder climate;
- Multiple partnerships within the complete R&D value chain
In order to face these industry challenges, most companies will need to answer the following key questions:
Key questions
- How can we accelerate the R&D cycle?
- How can we optimize & manage our portfolio?
- How should we manage our Intellectual Property?
Deloitte offering - Selected approaches & credentials
Deloitte has helped several big life sciences companies:
- To Improve R&D governance in the drug development process
- To streamline the different clinical R&D process flows
- To better use the clinical data in order to improve safety management, risk management and diminish regulatory exposure.
Material on this website is © 2013 Deloitte Global Services Limited, or a member firm of Deloitte Touche Tohmatsu Limited, or one of their affiliates. See Legal for copyright and other legal information.
Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee, and its network of member firms, each of which is a legally separate and independent entity. Please see www.deloitte.com/about for a detailed description of the legal structure of Deloitte Touche Tohmatsu Limited and its member firms.